JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol.6, no.7, 2017 (SCI-Expanded)
Background-Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically III VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm.